

ANUH PHARMA LTD.


CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED ON 31ST DECEMBER, 2015
 Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

₹ in Lacs

Sr. No.	Particulars	Unaudited				Audited	
		3 months ended on			Year to Date ended on		Previous year ended 31/03/2015
		31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014	
PART-I							
1	Income From Operations						
a	Net Sales Income from Operations (Net of Excise duty)	7,724.90	8,990.74	6,505.41	25,289.13	21,051.86	28,042.48
b	Other Operating Income	121.52	156.38	126.75	385.78	228.69	326.57
	Total income from Operations (net):-	7,846.42	9,147.12	6,632.16	25,674.91	21,278.55	28,369.05
2	Expenditure						
a	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(593.79)	(174.85)	332.88	(1,159.67)	(535.05)	212.08
b	Cost of Materials Consumed	6,656.12	7,014.39	4,772.87	20,659.98	17,000.08	21,821.82
c	Purchase of Stock -In-Trade	-	-	2.29	-	2.29	117.41
d	Employees Benefit Expense	170.08	171.42	144.13	488.07	417.49	562.46
e	Processing Charges	181.07	174.39	185.94	561.14	596.62	756.91
f	Power Fuel & Other Utility	107.42	105.95	74.58	299.74	244.77	322.19
g	Depreciation and amortisation expenses	62.99	54.87	50.29	168.36	140.29	327.35
h	Other Expenses	525.40	539.29	289.08	1,528.61	1,044.94	1,284.42
	Total Expenses :-	7,109.29	7,885.47	5,852.08	22,556.23	18,911.44	25,404.44
3	Profit From Operation before other income, Finance Costs & Exceptional Items (1-2)	737.13	1,261.65	780.08	3,118.68	2,367.11	2,964.61
4	Other Income	81.94	52.75	144.35	221.47	356.57	504.88
b	Exchange Gain/(Loss)	(26.53)	(156.22)	(72.07)	(242.04)	(220.59)	(278.40)
5	Profit from ordinary activities before finance costs & Exceptional Items(3+4)	772.55	1,158.18	852.36	3,098.12	2,503.09	3,191.09
6	Finance Costs	1.03	0.17	1.19	1.26	2.21	5.02
7	Profit from ordinary activities after finance costs but before Exceptional Items(5-6)	771.52	1,158.01	851.17	3,096.86	2,500.89	3,186.07
8	Exceptional Items	-	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before Tax (7+8)	771.52	1,158.01	851.17	3,096.86	2,500.89	3,186.07
10	Tax Expenses	250.00	415.00	282.00	1,030.00	800.00	986.95
11	Profit / (Loss) from ordinary activities after Tax (9-10)	521.52	743.01	569.17	2,066.86	1,700.89	2,199.12
12	Extraordinary Item (Net of Tax Expenses)	-	-	-	-	-	-
13	Net Profit(+) / Loss(-) for the period (11-12)	521.52	743.01	569.17	2,066.86	1,700.89	2,199.12
14	Share of profit / (Loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit(+) / Loss(-) after taxes, minority interest and share of profit of profit / (loss) of associates (13+14+15)	521.52	743.01	569.17	2,066.86	1,700.89	2,199.12
17	Paid up Equity Share Capital (Face value of ₹ 5/- each)	1,252.80	1,252.80	417.60	1,252.80	417.60	417.60
18	Reserves excluding Revaluation Reserves as per Balance sheet of Previous Accounting Year						9,672.12
19	Earning per Share(EPS) Face Value of Rs.5/-						
i	Earning Per Share(before Extraordinary Items) (not annualised)						
(a)	Basic	2.08 #	2.97 #	6.81	8.25 #	20.37	26.33
(b)	Diluted	2.08 #	2.97 #	6.81	8.25 #	20.37	26.33
ii	Earning Per Share(after Extraordinary Items) (not annualised)						
(a)	Basic	2.08 #	2.97 #	6.81	8.25 #	20.37	26.33
(b)	Diluted	2.08 #	2.97 #	6.81	8.25 #	20.37	26.33

FOR ANUH PHARMA LIMITED



DIRECTOR

PART II		Unaudited				Audited	
Sr. No.	Particulars	Quarter Ended			Year to Date ended		Previous year ended 31/03/2015
		Dec 2015	Sep 2015	Dec 2014	Dec 2015	Dec 2014	
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	-Number of Shares	7,346,309	7,323,809	2,924,342	7,346,309	2,924,342	2,924,342
	-Percentage of Shareholding	29.32	29.23	35.01	29.32	35.01	35.01
2	Promoters & Promoter group Shareholding						
a	Pledged/Encumbered						
	-Number of Shares	NII	NII	NII	NII	NII	NII
	-Percentage of Shares(as a % of the total share holding of promoter and promoter group)						
	-Percentage of shares(as a % of the total share capital of the company)						
b	Non Encumbered						
	-Number of Shares	17,709,691	17,732,191	5,427,658	17,709,691	5,427,658	5,427,658
	-Percentage of Shares(as a % of the total share holding of promoters and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	-Percentage of shares(as a % of the total share capital of the company)	70.68	70.77	64.99	70.68	64.99	64.99

Sr. No.	Particulars	3 months ended 31st December '15
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	10
	Disposed of during the quarter	10
	Remaining unresolved at the end of the quarter	-


NOTE:

- The above Financial Results were reviewed by the Audit Committee and taken on record by the Board of Director of the Company at their Meeting hold on 12th February, 2016.
- The Company's operation fall under single segment namely "Bulk Drugs & Chemicals".
- The above is an extract of the detailed format of Quarterly Financial Results for the Quarter and Nine months ended on 31st December, 2015, filed with the Stock Exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Nine months Financial Results on the Stock Exchange website viz. www.bseindia.com and on the Company's website(i.e.) www.anuhpharma.com.
- EPS reported at mark # is after giving effect to the issue of Bonus Shares in the ratio of 2 Bonus Shares for each existing share. Hence, comparable EPS at mark # would be Rs.6.24/- for the quarter ended on 31/12/2015, Rs. 8.91/- for the previous quarter ended on 30/09/2015 and Rs.24.75/- for the Nine Months ended on 31/12/2015.

Place : Mumbai

Date : 12th February, 2016

FOR ANUH PHARMA LIMITED



DIRECTOR

S. I. MOGUL & CO.
CHARTERED ACCOUNTANTS



73-B MITTAL COURT, NARIMAN POINT, MUMBAI 400021, INDIA
TEL: (91 22) 22842093, 22842159 | FAX: (91 22) 22822743 | E-MAIL: SIMCO@SIMOGUL.COM | WEBSITE: SIMOGUL.COM

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT


**TO THE BOARD OF DIRECTORS OF
ANUH PHARMA LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **Anuh Pharma Limited ("Company")** for the period ended on December 31, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement ("**SRE**") 2410, *'Review of Interim Financial Information performed by the Independent Auditor of the Entity'* issued by the Institute of Chartered Accountants of India ("**ICAI**"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W



S. I. Mogul

S. I. Mogul
Partner

Membership No. 5572

Mumbai, India: February 12, 2016